Why the study?
Does pharmacologic Lp(a) lowering reduce cardiovascular events in patients with elevated Lp(a) across secondary and primary prevention settings?
Does pharmacologic Lp(a) lowering reduce cardiovascular events in patients with elevated Lp(a) across secondary and primary prevention settings?
Answers are grounded in this paper and cite their sources.
This editorial argues that the neutral topline results of the secondary-prevention Lp(a)HORIZON trial do not invalidate Lp(a) as a causal risk marker for risk assessment, and highlights the need to evaluate earlier intervention in primary prevention trials.
Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor associated with atherosclerotic cardiovascular disease through proatherogenic, proinflammatory, and prothrombotic mechanisms. The neutral primary outcome of the Lp(a)HORIZON trial, despite pharmacologic Lp(a) lowering with pelacarsen, challenges assumptions about the clinical benefits of targeting Lp(a) in patients with established cardiovascular disease. However, these findings do not necessarily invalidate Lp(a) as a causal risk factor or the clinical value of measuring Lp(a). Lp(a)HORIZON primarily tested whether lowering Lp(a) after established disease reduces recurrent events, which is a different question from whether lifelong exposure to elevated Lp(a) contributes to disease development or whether earlier intervention can prevent first cardiovascular events. Ongoing primary- and mixed-prevention trials may help address this distinction. The Lp(a) experience highlights the importance of separating risk assessment from therapeutic efficacy and raises broader questions about the timing, magnitude, and duration of biomarker-targeted interventions. Adaptive guideline frameworks and AI-assisted evidence synthesis may help integrate emerging trial data more rapidly while preserving rigorous human clinical judgment.
No takes yet. Share an insight, caveat, or question.
Krittanawong et al. (2026) conducted an editorial in Elevated Lipoprotein(a) and established atherosclerotic cardiovascular disease (n=8,323). Pelacarsen vs. Placebo was evaluated on Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and urgent coronary revascularization requiring hospitalization.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: